

9th International Conference and Exhibition on

Advanced Cell and Gene Therapy

March 21-22, 2019 | Rome, Italy

Stem cell therapy for Crigler Najjar syndrome type I

Sharmila Fagoonee¹, Elvira Smeralda Famulari², Victor Navarro-Tableros³, Maria Beatriz Herrera Sanchez³, Giulia Bortolussi⁴, Marta Gai², Lorenzo Silengo², Emanuela Tolosano², Ciro Tetta², Andrés Fernando Muro⁴, Giovanni Camussi², and Fiorella Altruda²

¹Institute of Biostructure and Bioimaging, CNR, Italy

²University of Turin, Italy

³Molecular Biotechnology Center, Italy

⁴ICGEB, Italy

⁵Unicyte AG, Switzerland

The Crigler Najjar syndrome type I (CNSI) is a rare recessive disorder caused by mutations in the *Ugt1a1* gene. There is no permanent cure except for liver transplantation, and current therapies present several shortcomings. Since stem cell-based therapy offers a promising alternative for the treatment of this disorder, we evaluated the therapeutic potential of a population of stem cells isolated from cryopreserved hepatocytes known as human liver stem cells (HLSC) in immune-compromised NOD SCID Gamma (NSG)/*Ugt1*^{-/-} mice, which closely mimic the pathological manifestations in CNSI patients. In order to assess whether HLSC expressed UGT1A1, decellularised mouse liver scaffolds were repopulated with these cells. After 15 days' culture in this 3D setting *ex vivo*, HLSC differentiated into hepatocyte-like cells expressing markers such as albumin and cytochrome 1a1. For the *in vivo* human cell engraftment and recovery experiments in the Crigler-Najjar mouse model, NSG/*Ugt1*^{-/-} mice were generated. A single dose of HLSC was injected in the liver parenchyma of 5 days old phototherapy-treated NSG/*Ugt1*^{-/-} pups and HLSC functionality and phenotype rescue were assessed *in vivo* at post-natal Day 21. HLSC expressed UGT1A1 *in vivo*, induced a decrease in serum unconjugated bilirubin, and improved phenotype and survival compared to untreated controls. A significant reduction in eosinophilic neurons was also observed in HLSC-injected mutant mice hippocampus and cerebellum reflecting recovery from brain damage versus controls. Our results show that HLSC express UGT1A1 *in vivo* and improve the phenotype and survival of NSG/*Ugt1*^{-/-} mice, and show promises for the treatment of CNSI.

Biography

Sharmila Fagoonee did her PhD thesis on heme and hemoglobin metabolism at the University of Turin. During her Post-doc studies, she started working in the field of Regenerative Medicine after a training at BIDMC, Harvard, Boston. As a CNR Researcher, she is currently studying new therapies and biomarkers for liver diseases. She is Co-Investigator in several research projects (Telethon, PRIN, Regional grants). She has published more than 142 scientific papers. She has served as Reviewer for several scientific journals, and is an Editorial Board Member of *Journal of Clinical Medicine and Minerva Biotecnologica*.

sharmila.fagoonee@unito.it

Notes: